QTTB Strangle Strategy
QTTB (Q32 Bio Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
QTTB (Q32 Bio Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $168.3M, a trailing P/E of 5.58, a beta of -0.23 versus the broader market, a 52-week range of 1.345-14.85, average daily share volume of 756K, a public-listing history dating back to 2018, approximately 28 full-time employees. These structural characteristics shape how QTTB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.23 indicates QTTB has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 5.58 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.
What is a strangle on QTTB?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current QTTB snapshot
As of June 29, 2026, spot at $14.29, ATM IV 225.10%, IV rank 30.46%, expected move 64.53%. The strangle on QTTB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on QTTB specifically: QTTB IV at 225.10% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 64.53% (roughly $9.22 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated QTTB expiries trade a higher absolute premium for lower per-day decay. Position sizing on QTTB should anchor to the underlying notional of $14.29 per share and to the trader's directional view on QTTB stock.
QTTB strangle setup
The QTTB strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With QTTB near $14.29, the first option leg uses a $15.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed QTTB chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 QTTB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $15.00 | N/A |
| Buy 1 | Put | $13.58 | N/A |
QTTB strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
QTTB strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on QTTB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on QTTB
Strangles on QTTB are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the QTTB chain.
QTTB thesis for this strangle
The market-implied 1-standard-deviation range for QTTB extends from approximately $5.07 on the downside to $23.51 on the upside. A QTTB long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current QTTB IV rank near 30.46% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on QTTB should anchor more to the directional view and the expected-move geometry. As a Healthcare name, QTTB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to QTTB-specific events.
QTTB strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. QTTB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move QTTB alongside the broader basket even when QTTB-specific fundamentals are unchanged. Always rebuild the position from current QTTB chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on QTTB?
- A strangle on QTTB is the strangle strategy applied to QTTB (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With QTTB stock trading near $14.29, the strikes shown on this page are snapped to the nearest listed QTTB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are QTTB strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the QTTB strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 225.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a QTTB strangle?
- The breakeven for the QTTB strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current QTTB market-implied 1-standard-deviation expected move is approximately 64.53%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on QTTB?
- Strangles on QTTB are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the QTTB chain.
- How does current QTTB implied volatility affect this strangle?
- QTTB ATM IV is at 225.10% with IV rank near 30.46%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.